Skip to main content
. 2024 Aug 28;5(9):101700. doi: 10.1016/j.xcrm.2024.101700

Figure 6.

Figure 6

Gemcitabine treatment reveals prolonged survival in two SHH-ATRT xenograft models

(A) Survival analysis of VUMC-ATRT-03 orthotopic xenograft-bearing mice treated with vehicle (black line, n = 8) and gemcitabine (red line, n = 8). The gemcitabine-treated group shows significant survival benefit over vehicle-treated mice (p = 0.003, log rank test).

(B) Survival analysis of VUMC-ATRT-01 orthotopic xenograft-bearing mice treated with vehicle (black line, n = 9), doxorubicin (blue line, n = 7), and gemcitabine (red line, n = 10). The gemcitabine-treated group shows significant benefit over vehicle and doxorubicin-treated mice (p = 0.0008, log rank test).

(C) p53 immunohistochemical staining (in brown) in VUM-ATRT-01 xenograft patches, isolated at final day of treatment. Gemcitabine-treated mice show a higher ratio of p53-positive nuclei in their tumors compared to vehicle-treated animals.

(D) SIRT1 immunohistochemical staining (in brown) in VUM-ATRT-01 xenograft patches, isolated at final day of treatment. Gemcitabine-treated mice show lower SIRT1 expression compared to vehicle-treated animals.